Arthritis Clinical Trials

This single arm, open-label study will assess the safety and efficacy with regard to reduction of signs and symptoms of treatment with tocilizumab in combination with methotrexate, in patients with moderate to severe active rheumatoid arthritis. Patients will receive tocilizumab 8mg/kg iv, every 4 weeks and methotrexate 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is <500 individuals.